1. The Fed's interest rate cuts are expected to boost funding deployment in the healthcare sector; 2. XLV's top holdings show strong profitability with a median revenue growth forecast of 6.53%; 3. U.S. drug pricing legislation targeting Medicaid has limited impact, and XLV's low expense ratio and high AUM position it favorably among peers.